- First monoclonal antibody licensed to
help control the clinical signs associated with atopic dermatitis
in dogs
- Targets and neutralizes interleukin-31
(IL-31), a key itch-inducing cytokine (protein) in canine atopic
dermatitis
- Provides convenience and long-lasting
relief from itch with one injection every four to eight weeks
- Joins Zoetis’ APOQUEL® (oclacitinib
tablet), giving the company two targeted treatment options to offer
veterinarians for canine patients with atopic dermatitis
Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Department
of Agriculture (USDA) has granted the company a license for
CYTOPOINT™, the first monoclonal antibody (mAb) therapy approved to
help provide sustained control of the clinical signs associated
with atopic dermatitis in dogs. CYTOPOINT targets and neutralizes
interleukin-31 (IL-31), a key protein involved in triggering itch
in dogs. It provides fast, effective relief of itching – the
hallmark sign of the allergic skin condition atopic dermatitis in
dogs – and offers the sustained efficacy and convenience of one
injection every four to eight weeks. CYTOPOINT helps improve the
long-term quality of life for dogs suffering from atopic dermatitis
and eases the related frustration and concern of their owners. It
is now available to all veterinarians in the United States.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20161221005906/en/
Cytopoint logo (Photo: Zoetis)
“As the owner of allergic pets, I understand the frustration
that my clients feel, and as a person with allergies myself, I
understand what my patients feel,” said Laura Stokking, PhD, DVM,
DACVD, Veterinary Specialty Hospital, San Diego, CA.* “With
CYTOPOINT, in a single injection we now have an excellent
opportunity to help control the itch without leading to any
secondary signs that can be more difficult to manage than the itch
itself.”
“CYTOPOINT results from our acquiring a deeper scientific
understanding of the causes of allergic skin conditions in dogs at
the molecular level and developing novel, targeted, effective
treatments based on these new insights,” said Dr. Catherine Knupp,
Executive Vice President and President, Research and Development at
Zoetis. “Veterinarians have told us that allergic dogs and their
owners have a variety of needs and we are proud to offer them two
innovative solutions with CYTOPOINT and with our oral tablet
therapy APOQUEL. These first-in-class medicines give veterinarians
effective, safe options to customize atopic dermatitis treatment
for canine patients, and I am very proud of the breakthrough
treatments our Zoetis team has developed.”
APOQUEL® (oclacitinib tablet) is the first Janus kinase
inhibitor approved by the U.S. Food and Drug Administration for
veterinary use to provide fast and safe itch relief for dogs at
least 12 months of age that have symptoms associated with allergic
dermatitis triggered by food, fleas or contact allergens, as well
as atopic dermatitis.
About CYTOPOINT
CYTOPOINT is a ready-to-use, sterile liquid injectable
containing a mAb specifically designed to target and neutralize
cytokine interleukin-31 (IL-31), a key cytokine (protein important
in cell-to-cell communication) involved in triggering the itch
associated with canine atopic dermatitis. It works by mimicking the
activity of natural antibodies to selectively bind and neutralize
IL-31, thus interrupting the itch cycle in atopic dogs.
CYTOPOINT begins working within 1 day and delivers 4 to 8 weeks
of relief from the clinical signs of canine atopic dermatitis,
allowing the damaged skin the chance to heal. In clinical studies
submitted to the USDA and published in Veterinary Dermatology,
treatment with CYTOPOINT at a minimum dose of 2 mg/kg resulted in a
significantly (P≤0.05) greater percentage reduction from baseline
in pruritus on days 1–49, and skin condition scores on days 7-561,
when compared to placebo.
It is safe for dogs of any age, even those with concomitant
diseases, and can be used with many common medications. Moreover,
because of its specificity in targeting IL-31, it has minimal
impact on normal immune responses.
The USDA granted Zoetis a conditional license for Canine Atopic
Dermatitis Immunotherapeutic (now branded as CYTOPOINT) in August
2015. During the conditional licensing period, Zoetis collected
valuable feedback from dermatology specialists, a small group of
general practice veterinarians, and pet owners to prepare for full
licensure.
About Atopic Dermatitis
Itching is among the most frequent complaints of pet owners,
affecting roughly 1 in 6 dogs whose owners seek veterinary help.2
There are a number of factors that can trigger an itch reaction,
such as infections, allergies and parasites—and approximately 15-20
percent of all itchy dogs will be diagnosed with atopic
dermatitis.2
CYTOPOINT is now available for veterinarians throughout the
United States. It brings mAb therapy – a fast-growing area of human
medicine – for the first time to veterinarians for use to treat
atopic dermatitis in canine patients. For more information, visit
www.cytopoint.com.
IMPORTANT SAFETY INFORMATION ABOUT APOQUEL
Do not use APOQUEL in dogs less than 12 months of age or those
with serious infections. APOQUEL may increase the chances of
developing serious infections, and may cause existing parasitic
skin infestations or pre-existing cancers to get worse. APOQUEL has
not been tested in dogs receiving some medications including some
commonly used to treat skin conditions such as corticosteroids and
cyclosporines. Do not use in breeding, pregnant, or lactating dogs.
Most common side effects are vomiting and diarrhea. APOQUEL has
been used safely with many common medications including
parasiticides, antibiotics and vaccines. For full Prescribing
Information, go to ZoetisUS.com/ApoquelPI.
About Zoetis
Zoetis is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on more
than 60 years of experience in animal health, Zoetis discovers,
develops, manufactures and markets veterinary vaccines and
medicines, complemented by diagnostic products and genetic tests
and supported by a range of services. Zoetis serves veterinarians,
livestock producers and people who raise and care for farm and
companion animals with sales of its products in more than 100
countries. In 2015, the company generated annual revenue of $4.8
billion with approximately 9,000 employees. For more information,
visit www.zoetis.com.
Forward-Looking
Statements: This press release contains forward-looking
statements, which reflect the current views of Zoetis with respect
to business plans or prospects, future operating or financial
performance, future guidance, future operating models, expectations
regarding newly approved products and other products and other
future events. These statements are not guarantees of future
performance or actions. Forward-looking statements are subject to
risks and uncertainties. If one or more of these risks or
uncertainties materialize, or if management's underlying
assumptions prove to be incorrect, actual results may differ
materially from those contemplated by a forward-looking statement.
Forward-looking statements speak only as of the date on which they
are made. Zoetis expressly disclaims any obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise. A further list and
description of risks, uncertainties and other matters can be found
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2015, including in the sections thereof captioned
“Forward-Looking Information and Factors That May Affect Future
Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on
Form 10-Q and in our Current Reports on Form 8-K. These filings and
subsequent filings are available online
at www.sec.gov, www.zoetis.com, or on request from
Zoetis.
* Dr. Laura Stokking has a consulting relationship with
Zoetis.
1 Data on file, Study Report No. C863R-US-12-018, Zoetis
LLC.
2 Data on file, IL-31 Positioning Research. IPSOS 2014. L-31
Pricing Research. SKP. 2015, Zoetis LLC.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161221005906/en/
ZoetisMedia:Elinore White, 973-443-2835
(o)elinore.y.white@zoetis.comorColleen White, 973-822-7203
(o)colleen.white@zoetis.comorInvestors:Steve Frank, 973-822-7141
(o)steve.frank@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024